Evolution of Poliovirus During an Outbreak: Sequential Type 3 Poliovirus Isolates from Several Persons Show Shifts of Neutralization Determinants

References

1. Almond J. W., Stanway G., Cann A. J., Westrop G., Evans D. M. A., Ferguson M., Minor P. D., Spitz M., Schild G. c. 1985; New poliovirus vaccines: a molecular approach. Vaccine 2:177–183
   [Google Scholar]
2. Böttiger M. 1971; Neutralization capacity of poliovirus type 3 antibodies tested against 5 different intratypic variants of poliovirus type 3. Archiv für die gesamte Virusforschung 35:231–255
   [Google Scholar]
3. Evans D. M. A., Minor P. D., Schild G. C., Almond J. W. 1983; Critical role of an eight amino acid sequence of VP1 in neutralization of poliovirus type 3. Nature; London: 304459–462
   [Google Scholar]
4. Evans D. M. A., Dunn G., Minor P. D., Schild G.C., Cann A. J., Stanway G., Almond J. W., Currey K., Maizel J. V. 1985; A single nucleotide change in the 5′ non-coding region of the genome of the Sabin type 3 poliovaccine is associated with increased neurovirulence. Nature; London: 314548–550
   [Google Scholar]
5. Ferguson M., Minor P. D., Magrath D. I., Ql Yi-Hua, Spitz M., Schild G. C. 1984; Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies. Journal of General Virology 65:197–201
   [Google Scholar]
6. Ferguson M., Evans D. M. A., Magrath D. I., Minor P. D., Almond J. W., Schild G. C. 1985; Induction of broadly reactive, type-specific neutralizing antibody to poliovirus type 3 by synthetic peptides. Virology 143:505–515
   [Google Scholar]
7. Hovi T., Cantell K., Huovilainen A., Kinnunen E., Kuronen T., Lapinleimu K., Pöyry T., Roivainen M., Salama N., Stenvik M., Silander A., Thoden C.-J., Salminen S., Weckström P. 1986; Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet i:1427–1432
   [Google Scholar]
8. Icenogle J. p., Minor P. D., Ferguson M., Hogle J. M. 1986; Modulation of humoral response to a 12-amino acid site on the poliovirion. Journal of Virology 60:297–301
   [Google Scholar]
9. Magrath D. I., Evans D. M. A., Ferguson M., Schild G. C., Minor P. D., Horaud F., Crainic R., Stenvik M., Hovi T. 1986; Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population. Journal of General Virology 67:899–905
   [Google Scholar]
10. Minor P. D., Evans D. M. A., Ferguson M., Schild G. C., Westrop G., Almond J. W. 1985; Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3. Journal of General Virology 66:1159–1165
    [Google Scholar]
11. Minor P. D., John A., Ferguson M., Icenogle J. P. 1986; Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. Journal of General Virology 67:693–706
    [Google Scholar]
12. Nottay B. K., Kew O. M., Hatch M. H., Heyward J. p., Obueskl J. F. 1981; Molecular variation of type 1 vaccine related and wild polioviruses during replication in humans. Virology 108:405–423
    [Google Scholar]